Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.

Hematology (Amsterdam, Netherlands) - 1 Jan 2013

Fujiwara Shin-ichiro, Muroi Kazuo, Hirata Yuji, Sato Kazuya, Matsuyama Tomohiro, Ohmine Ken, Suzuki Takahiro, Ozaki Katsutoshi, Mori Masaki, Nagai Tadashi, Tanaka Akira, Ozawa Keiya

Abstract excerpt

CD25 (interluekin-2 receptor) expression in diffuse large B-cell lymphoma (DLBCL) cells has been not examined. To characterize CD25(+) DLBCL, 123 patients, who were newly diagnosed with DLBCL, were analyzed by single-color flow cytometry (FCM). CD25-positivity was significantly higher in DLBCL patients (n = 123; mean ± SD, 27.8 ± 30.6%) than in those with reactive lymphadenopathy (n = 16; mean ± SD, 8.6 ± 4.3%)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Flow Cytometry

Share to Interleukin-2 Receptor alpha Subunit

Share to Lymphoma, Large B-Cell, Diffuse

Share to Prognosis

Share to Treatment Outcome

Source

Identifiers

PMID: 22981118
DOI: 10.1179/1607845412Y.0000000024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.PMID 22981118Read ↗

De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.Semantic proximity Read ↗

CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).Semantic proximity Read ↗

De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.Semantic proximity Read ↗

De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.Semantic proximity Read ↗

CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.Semantic proximity Read ↗

Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell.Semantic proximity Read ↗

[CD5- and CD10-positive MYC and BCL2 double-expressor diffuse large B-cell lymphoma with MYD88L265P mutation: a case report and literature review].Semantic proximity Read ↗

De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.Semantic proximity Read ↗

Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes.Semantic proximity Read ↗

CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometrySemantic proximity Read ↗

Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion.Semantic proximity Read ↗

CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.